Media Articles Related to Boniva Injection (Ibandronic Acid)
Osteoporosis linked with heart disease in older people
Source: Bones / Orthopedics News From Medical News Today [2015.06.29]
University of Southampton scientists have discovered a link between coronary heart disease and osteoporosis, suggesting both conditions could have similar causes.
Drug approved to treat osteoporosis shows promise in pre-clinical diabetes research
Source: Bones / Orthopedics News From Medical News Today [2015.06.19]
American scientists have discovered that a drug commonly used to treat osteoporosis in humans also stimulates the production of cells that control insulin balance in diabetic mice.
Use of osteoporosis drugs have dropped following media reports of safety concerns
Source: Bones / Orthopedics News From Medical News Today [2015.06.16]
Following a decade of steady growth, use of bisphosphonates--medications that are effective for treating osteoporosis--declined in the United States by more than 50% from 2008 to 2012.
Men Should Be Screened for Osteoporosis, Too
Source: MedicineNet Mens Health Specialty [2015.05.15]
Title: Men Should Be Screened for Osteoporosis, Too
Category: Health News
Created: 5/15/2015 12:00:00 AM
Last Editorial Review: 5/15/2015 12:00:00 AM
Osteoporosis Pictures Slideshow: Super Foods for Your Bones
Source: MedicineNet Vitamins and Calcium Supplements Specialty [2015.04.24]
Title: Osteoporosis Pictures Slideshow: Super Foods for Your Bones
Created: 2/3/2009 12:00:00 AM
Last Editorial Review: 4/24/2015 12:00:00 AM
Published Studies Related to Boniva Injection (Ibandronic Acid)
Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. 
BACKGROUND AND OBJECTIVE: Despite their widespread use in metastatic bone disease, some bisphosphonate drugs are associated with adverse events (AEs), particularly renal toxicity, adding to treatment burdens and increasing healthcare costs. Ibandronic acid is a single-nitrogen bisphosphonate with high efficacy against bone events and metastatic bone pain, and a renal safety profile compar- able to that of placebo. In this study, the safety of ibandronic acid was examined over a period of 4 years... CONCLUSION: This 96-week open-label safety extension of a phase III, placebo-controlled trial demonstrates that long-term use of intravenous ibandronic acid is well tolerated.
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). [2005.12]
CONCLUSIONS: Significantly more women with postmenopausal osteoporosis preferred once-monthly ibandronate therapy to once-weekly alendronate therapy, and found the once-monthly regimen to be more convenient. Ease of following a treatment regimen for a long time was the most common reason given for the patients' preferences.
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone
metastases from breast cancer: a randomised, open label, non-inferiority phase 3
the treatment of metastatic breast cancer to bone... INTERPRETATION: Our results suggest that zoledronic acid is preferable to
Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study. [2010.03]
AIMS: To describe renal function monitoring practice in patients with metastatic bone disease (MBD) treated with IV zoledronic acid (ZA) and oral ibandronic acid (IA), the management pathways and NHS hospital resources used... CONCLUSION: Although limited by retrospective design, these results demonstrate that in many patients, CrCl is not calculated before or during treatment with bisphosphonates. Renal function deteriorated in many patients during therapy. In view of these effects, practice should be reviewed to ensure appropriate dosing.
Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. [2008.12]
PURPOSE: This trial is the first to compare directly the clinical response to and safety of oral and intravenous (IV) ibandronic acid for metastatic bone disease... CONCLUSION: Oral and IV ibandronic acid for bone metastases have similar efficacy and tolerability.
Clinical Trials Related to Boniva Injection (Ibandronic Acid)
BONVIVA(Ibandronate) PMS(Post-marketing Surveillance ) [Recruiting]
BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy. [Active, not recruiting]
This single arm study will assess patient preference for monthly Bonviva, versus daily or
weekly alendronate or risedronate, in the treatment of postmenopausal osteoporosis. Patients
currently on a daily or weekly regimen of bisphosphonate therapy (alendronate or risedronate)
will answer a questionnaire to identify patients who may benefit from a monthly Bonviva
regimen. Eligible patients will then discontinue their present bisphosphonate treatment, and
switch to monthly Bonviva 150mg po. At the beginning and end of Bonviva treatment, all
patients will complete an Osteoporosis Patient Satisfaction Questionnaire. The anticipated
time on study treatment is 3-12 months, and the target sample size is 500+ individuals.
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva [Completed]
This 2 arm study will assess the long-term efficacy and safety of oral treatment with 100mg
or 150mg Bonviva in women with post-menopausal osteoporosis who have previously completed
Bonviva study BM16549 (MOBILE study). Patients will receive Bonviva either 100mg po monthly,
or 150mg po monthly. Patients will also receive daily supplementation with vitamin D and
calcium. The anticipated time of study treatment is 2+ years, and the target sample size is
BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance) [Recruiting]
BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis [Active, not recruiting]
This 2 arm study will assess the impact of Bone Marker Feedback (BMF), using blood sampling
and communication of the results at 2 months, on adherence to monthly Bonviva (150mg po) in
women with post-menopausal osteoporosis. Patients will be randomized into either 1) a group
which receives bone marker feedback or 2)a group which does not receive feedback on the
results. The study will also assess patient satisfaction with treatment with once monthly
Bonviva. The anticipated time on study treatment is 3-12 months, and the target sample size
is 500+ individuals.